To understand the targets of DUSP16 in NPC cisplatin resistance, the activation of MAPKs, including ERK, JNK, and p38, was assessed in both HK-1 and C666-1 cells upon treatment with 5 and 30 μg/mL cisplatin, respectively. The gene discussed is DUSP16; the disease is nasopharyngeal carcinoma.